#1 Clinical Trials Search in Europe

Procarbazine

Procarbazine is a chemotherapy drug that has been the subject of several clinical trials, particularly in the treatment of various types of cancer, including brain tumors and lymphomas. This article explores the use of Procarbazine in different clinical trial settings, its potential benefits, and its combination with other treatments to improve patient outcomes.

Table of Contents

What is Procarbazine?

Procarbazine is a chemotherapy drug used to treat various types of cancer. It belongs to a class of medications known as alkylating agents, which work by stopping or slowing the growth of cancer cells in your body. Procarbazine is also known by its brand name Natulan[1]. Another common synonym for procarbazine is Matulan[2].

What Conditions Does Procarbazine Treat?

Procarbazine is primarily used to treat several types of cancers and tumors, including:

  • Brain and Central Nervous System Tumors: This includes glioblastoma multiforme, astrocytoma, and oligodendroglioma[3][4].
  • Hodgkin’s Lymphoma: Particularly in advanced stages of the disease[1].
  • Primary Central Nervous System Lymphoma (PCNSL): A rare type of non-Hodgkin lymphoma that affects the brain and spinal cord[5].

How Does Procarbazine Work?

Procarbazine is a type of drug called an alkylating agent. It works by damaging the DNA of cancer cells, which prevents them from dividing and growing. This action helps to stop or slow the spread of cancer in your body[3].

How is Procarbazine Administered?

Procarbazine is typically given orally in the form of capsules or tablets. The dosage and schedule can vary depending on the specific condition being treated and other factors. Here are some common administration methods:

  • Daily doses for a specific number of days, followed by a rest period[6].
  • As part of a combination therapy regimen, where it’s taken on specific days along with other medications[5].
  • In some cases, it may be given in cycles, with treatment periods followed by rest periods[7].

Always follow your doctor’s instructions carefully when taking procarbazine.

Procarbazine in Combination Therapies

Procarbazine is often used as part of combination chemotherapy regimens. Some common combinations include:

  • PCV: This stands for Procarbazine, CCNU (lomustine), and Vincristine. It’s commonly used for brain tumors[2].
  • BEACOPP: This regimen includes Bleomycin, Etoposide, Adriamycin (doxorubicin), Cyclophosphamide, Oncovin (vincristine), Procarbazine, and Prednisone. It’s used for advanced Hodgkin’s lymphoma[1].
  • RL-MPV: This stands for Rituximab, Lenalidomide, Methotrexate, Procarbazine, and Vincristine. It’s being studied for primary CNS lymphoma[5].

Potential Side Effects

Like all chemotherapy drugs, procarbazine can cause side effects. Some potential side effects may include:

  • Nausea and vomiting
  • Loss of appetite
  • Fatigue
  • Lowered blood cell counts, which can increase risk of infection or bleeding
  • Neurological effects, such as confusion or dizziness

Your healthcare team will monitor you closely for these and other side effects during treatment[7].

Ongoing Research and Clinical Trials

Researchers continue to study procarbazine to find new ways to use it effectively and to understand its long-term effects. Some areas of ongoing research include:

  • Comparing procarbazine-containing regimens with newer therapies for brain tumors[8].
  • Studying procarbazine in combination with other drugs for recurrent brain tumors[7].
  • Investigating the effectiveness of procarbazine-containing regimens in specific patient groups, such as older adults with brain lymphomas[9].

These studies aim to improve treatment outcomes and quality of life for patients receiving procarbazine-based therapies.

Aspect Details
Cancer Types Studied Advanced Hodgkin’s lymphoma, Recurrent glioblastoma multiforme, Malignant gliomas, Primary CNS lymphoma
Common Combinations BEACOPP regimen, PCV chemotherapy, Combination with lomustine, thalidomide, methotrexate
Administration Typically oral, dosage and schedule vary by trial
Primary Outcomes Measured Overall response rate, Progression-free survival, Overall survival
Secondary Outcomes Safety profile, Quality of life, Duration of response
Notable Trials NCT02800447 (Hodgkin’s lymphoma), NCT01737346 (Recurrent glioblastoma), NCT05425654 (Primary CNS lymphoma)
Potential Benefits Improved survival rates, Better response rates, Potential for combination with newer therapies

FAQ

  • What is Procarbazine and how does it work? Procarbazine is a chemotherapy drug that works by stopping cancer cells from dividing and growing. It is often used in combination with other drugs to treat various types of cancer, particularly brain tumors and lymphomas.
  • In which types of cancer is Procarbazine being studied? Based on the clinical trials data, Procarbazine is being studied in various cancers, including advanced Hodgkin's lymphoma, recurrent glioblastoma multiforme, malignant gliomas, and primary central nervous system lymphoma.
  • How is Procarbazine typically administered in clinical trials? Procarbazine is usually administered orally, often as part of a combination therapy regimen. The dosage and schedule can vary depending on the specific trial and treatment protocol.
  • What are some common drug combinations that include Procarbazine? Common combinations include BEACOPP (which includes Procarbazine along with other drugs for Hodgkin's lymphoma), PCV (Procarbazine, CCNU, and Vincristine for brain tumors), and combinations with drugs like lomustine, thalidomide, and methotrexate.
  • What are researchers hoping to achieve by studying Procarbazine in clinical trials? Researchers are aiming to determine the effectiveness of Procarbazine in improving survival rates, progression-free survival, and overall response rates in various cancers. They are also studying its safety profile and potential side effects when used alone or in combination with other treatments.

Ongoing Clinical Trials on Procarbazine

  • Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany

  • Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany

  • Study of Temozolomide and Lomustine Followed by Radiotherapy versus Standard Treatment in Patients with Newly Diagnosed Grade 2 or 3 Glioma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Glioblastoma multiforme: A fast-growing and aggressive brain tumor that forms from glial cells (cells that support nerve cells).
  • Hodgkin's lymphoma: A type of cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system.
  • BEACOPP regimen: A combination chemotherapy treatment that includes Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Oncovin (Vincristine), Procarbazine, and Prednisone.
  • PCV chemotherapy: A combination chemotherapy regimen that includes Procarbazine, CCNU (Lomustine), and Vincristine, often used to treat brain tumors.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Autologous stem cell transplantation: A procedure where a patient's own stem cells are collected, stored, and then reinfused after high-dose chemotherapy to help restore the body's ability to produce blood cells.
  • IDH1/2 mutation: A genetic alteration found in some brain tumors that can affect how the tumor grows and responds to treatment.

References

  1. https://clinicaltrials.gov/study/NCT02800447
  2. https://clinicaltrials.gov/study/NCT01737346
  3. https://clinicaltrials.gov/study/NCT00002840
  4. https://clinicaltrials.gov/study/NCT00004004
  5. https://clinicaltrials.gov/study/NCT05425654
  6. https://clinicaltrials.gov/study/NCT00003564
  7. https://clinicaltrials.gov/study/NCT00079092
  8. https://clinicaltrials.gov/study/NCT00003293
  9. https://clinicaltrials.gov/study/NCT00989352